<DOC>
	<DOCNO>NCT00002389</DOCNO>
	<brief_summary>To compare durability viral load response follow 48 week treatment 1592U89/lamivudine ( 3TC ) /zidovudine ( ZDV ) versus 3TC/ZDV alone . To compare early antiviral activity follow 16 week treatment 1592U89/3TC/ZDV versus 3TC/ZDV alone demonstrated proportion subject viral load &lt; 400 copies/ml , plasma HIV-1 RNA profile CD4+ profile . To assess safety tolerance follow 16 48 week treatment 1592U89/3TC/ZDV versus 3TC/ZDV alone .</brief_summary>
	<brief_title>The Safety Effectiveness Lamivudine Plus Zidovudine , Used With Without 1592U89 , HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs</brief_title>
	<detailed_description>This study compare safety efficacy 1592U89 combination 3TC ZDV versus control therapy 3TC ZDV alone . If patient two consecutive HIV-1 RNA measurement &gt; = 400 copies/ml ( perform least one week apart ) option switch open-label therapy 1592U89/3TC/ZDV , receive remain randomize treatment , discontinue study medication . If criterion meet , patient continue randomly assign therapy last patient complete 48 week therapy . Once patient enter open-label phase , investigator may add substitute non-nucleoside reverse transcriptase inhibitor , nucleoside reverse transcriptase inhibitor , protease inhibitor 3TC and/or ZDV accord standard practice patient enter open-label phase .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Local treatment Kaposi 's sarcoma . Hematologic supportive therapy GMCSF , GCSF , erythropoietin . Patients must : HIV1 infection document license HIV1 antibody ELISA confirm either Western blot detection HIV1 antibody positive HIV1 blood culture . One screen CD4 lymphocyte cell count &gt; = 100 cells/mm3 within 14 day prior study drug administration . No active ongoing AIDSdefining opportunistic infection disease . Signed , inform consent parent legal guardian patient 18 year age . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Malabsorption syndrome gastrointestinal dysfunction might interfere drug absorption render patient unable take oral medication . Serious medical condition diabetes , congestive heart failure , cardiomyopathy , cardiac dysfunction , , opinion investigator , would compromise safety patient . Concurrent Medication : Excluded : Foscarnet therapy . Immunomodulating agent systemic corticosteroid , interleukin , thalidomide , anticytokine agent , interferon . Cytotoxic chemotherapeutic agent antioxidant . Concurrent Treatment : Excluded : Radiation therapy . Patients follow prior condition exclude : History clinically relevant pancreatitis hepatitis within last 6 month . Prior Medication : Excluded : Prior antiretroviral therapy . Vaccination within past 3 month give part investigational HIV vaccine trial . Chemotherapeutic agent within 30 day study drug administration . Immunomodulating agent systemic corticosteroid , interleukin interferon , within 30 day study drug administration . Prior Treatment : Excluded : Radiation therapy within 30 day study period . Current alcohol illicit drug use , opinion investigator , may interfere patient 's ability comply dose schedule protocol evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 1998</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>CD4 Lymphocyte Count</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
	<keyword>abacavir</keyword>
</DOC>